FilingReader Intelligence
Sinopharm to continue $117m share buyback for working capital
March 27, 2025 at 08:04 PM UTC•By FilingReader AI
China National Medicines Corp (Sinopharm) has released a series of announcements concerning its operational and financial strategies. The company will seek shareholder approval to continue its plan to use no more than RMB 854 million (approximately $117 million USD) in idle funds raised from share issuances to supplement working capital.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Sinopharm 2024 Annual ReportMarch 19, 2025 at 01:04 PM UTC
China International Capital Corporation Limited's review opinion on Sinopharm Group Co., Ltd.'s plan to continue using part of the idle raised funds to temporarily supplement its working capitalMarch 19, 2025 at 01:04 PM UTC
Summary of Sinopharm 2024 Annual ReportMarch 19, 2025 at 01:04 PM UTC
Tianjianshen〔2025〕No. 1-69-241231 Special Report on Fund Raising of Sinopharm GroupMarch 19, 2025 at 01:04 PM UTC
Sinopharm Group's announcement on the plan to use part of the idle raised funds to temporarily supplement working capitalMarch 19, 2025 at 01:04 PM UTC
Sinopharm Group's special report on the deposit and actual use of raised funds in 2024March 19, 2025 at 01:04 PM UTC
Sinopharm Group's announcement on the status of routine related-party transactions in 2024 and expected routine related-party transactions in 2025March 19, 2025 at 01:04 PM UTC
China International Capital Corporation Limited's special verification report on the deposit and use of raised funds of Sinopharm Group China Pharmaceutical Co., Ltd. in 2024March 19, 2025 at 01:04 PM UTC
Sinopharm Group's Continuous Risk Assessment Report on Sinopharm Group Finance Co., Ltd.March 19, 2025 at 01:04 PM UTC
Sinopharm Group Announcement on 2024 Annual Profit Distribution PlanMarch 19, 2025 at 01:04 PM UTC
600511_Sinopharm Group_2024_Internal Control Evaluation ReportMarch 19, 2025 at 01:04 PM UTC
Tianjianshen〔2025〕No. 1-68-Sinopharm Group 2024 Internal Control Audit ReportMarch 19, 2025 at 01:04 PM UTC
SSE:600511•Shanghai Stock Exchange
News Alerts
Get instant email alerts when China National Medicines Corp publishes news
Free account required • Unsubscribe anytime